Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association
Carmine Zoccali(Biogem), Andrzej Więcek(Medical University of Silesia), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki), Christoph Wanner(Universitätsklinikum Würzburg), Patrick B. Mark(Queen Elizabeth University Hospital), Charles J. Ferro(Queen Elizabeth Hospital Birmingham), Marcin Adamczak(Medical University of Silesia), Michel Burnier(Gdańsk Medical University), Ziad A. Massy(Inserm), Raymond Vanholder(Ghent University Hospital), Peter Kotanko(Renal Research Institute), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Francesca Mallamaci(Società Italiana di Nefrologia)
Cited by 312
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
|European Heart Journal|2024|1.9k